title: Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma.
abstract: In order to evaluate the clinical significance of soluble interleukin-2 receptor (sIL-2R) levels in the serum of patients with Hodgkin's disease (HD), we tested the pretreatment sera of 82 patients. The HD patients had significantly higher sIL-2R levels than normal controls (4787 U/ml versus 290 U/ml; P less than 0.001). In patients presenting with B-symptoms, the median sIL-2R levels were significantly higher than in patients without B-symptoms (7978 versus 2128 U/ml; P less than 0.01). Patients in stage IVB had the highest sIL-2R levels (10,450 U/ml). Of 77 patients evaluable for response, all patients with sIL-2R levels less than 1000 U/ml achieved complete remission and no relapses occurred in this group after a median of 20 months. The fact that sIL-2R levels dropped after therapy, even in patients who suffered from progressive disease, suggests that Hodgkin and Reed-Sternberg cells are only a minor source of sIL-2R in HD. Therefore sIL-2R levels are of limited value as a marker of disease activity. However, pretreatment sIL-2R levels less than 1000 U/ml define a subgroup of adult HD patients with an excellent prognosis, and this fact might be helpful for the design of more custom-tailored therapy programs.
authors.affiliation: Laboratories of Immunology and Tumor Biology, Medizinische Klinik, University of Cologne, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Gause
authors.forename: V
authors.initials: V
authors.lastname: Roschansky
authors.forename: A
authors.initials: A
authors.lastname: Tschiersch
authors.forename: K
authors.initials: K
authors.lastname: Smith
authors.forename: D
authors.initials: D
authors.lastname: Hasenclever
authors.forename: R
authors.initials: R
authors.lastname: Schmits
authors.forename: V
authors.initials: V
authors.lastname: Diehl
authors.forename: M
authors.initials: M
authors.lastname: Pfreundschuh
mesh_terms: D000293:Adolescent; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D001799:Blood Sedimentation; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000097:blood* / Q000473:pathology / Q000628:therapy; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012074:Remission Induction
chemical_list: D015375:Receptors, Interleukin-2; D007770:L-Lactate Dehydrogenase; D000469:Alkaline Phosphatase